This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Is a Surprise Coming for GSK This Earnings Season?
by Zacks Equity Research
GSK is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
GSK Gears Up for Q4 Earnings: Will It Surpass Estimates?
by Zacks Equity Research
We expect GSK's specialty products like Arexvy, Cabenuva, Dovato, Bexsero, Trelegy Ellipta and Shingrix to drive fourth-quarter sales performance.
Analysts Estimate Bristol Myers Squibb (BMY) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Incyte (INCY) Banks on Opzelura as Jakafi Faces Competition
by Zacks Equity Research
Incyte (INCY) is likely to rebound in 2024 on the solid growth of Opzelura and additional label expansions.
What You Need to Know Ahead of Bristol-Myers (BMY) Q4 Earnings
by Zacks Equity Research
Investors are likely to focus on Opdivos demand, along with an incremental contribution from newer drugs, when Bristol-Myers (BMY) reports Q4 results.
Why GSK (GSK) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Novartis (NVS) to Report Q4 Earnings: Is a Beat in Store?
by Zacks Equity Research
Novartis' (NVS) key drugs, Entresto, Kisqali and Pluvicto, are likely to have fueled its top and bottom-line numbers in the fourth quarter.
GSK (GSK) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Glaxo (GSK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
GSK (GSK) Stock Dips While Market Gains: Key Facts
by Zacks Equity Research
GSK (GSK) closed at $39.53 in the latest trading session, marking a -0.38% move from the prior day.
GSK (GSK) Declines More Than Market: Some Information for Investors
by Zacks Equity Research
GSK (GSK) closed at $39.88 in the latest trading session, marking a -0.55% move from the prior day.
Biotech Stock Roundup: REGN Down on Eylea Update, MRNA Gains on Preliminary Results
by Zacks Equity Research
Preliminary Q4 and 2023 results from Regeneron (REGN) and Moderna (MRNA) were key highlights this week in the biotech sector.
GSK to Buy Private Biotech, Strengthen Respiratory Pipeline
by Zacks Equity Research
GSK's proposed acquisition of Aiolos is set to add the latter's long-acting anti-TSLP monoclonal antibody, AIO-001, to GSK's broad portfolio of respiratory products.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
GSK (GSK) Rises But Trails Market: What Investors Should Know
by Zacks Equity Research
The latest trading day saw GSK (GSK) settling at $39.64, representing a +1.1% change from its previous close.
Why Glaxo (GSK) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Glaxo (GSK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
GSK (GSK) Rises As Market Takes a Dip: Key Facts
by Zacks Equity Research
GSK (GSK) concluded the recent trading session at $37.51, signifying a +1.21% move from its prior day's close.
GSK (GSK) Rises Higher Than Market: Key Facts
by Zacks Equity Research
In the most recent trading session, GSK (GSK) closed at $37.10, indicating a +0.24% shift from the previous trading day.
Merck's (MRK) Chronic Cough Drug Gets Another CRL From FDA
by Zacks Equity Research
Per the FDA, the data submitted by Merck (MRK) for its chronic cough drug did not provide sufficient evidence to prove its clinical benefit in patients.
GSK, Hansoh Ink Deal to Develop Lung Cancer ADC Candidate
by Zacks Equity Research
GSK enters into an exclusive licensing agreement with China-based Hansoh to develop and commercialize the latter's lung cancer candidate, HS-20093.
GSK (GSK) Stock Moves -0.85%: What You Should Know
by Zacks Equity Research
The latest trading day saw GSK (GSK) settling at $36.19, representing a -0.85% change from its previous close.
The Zacks Analyst Blog Highlights Novo Nordisk, Eli Lilly, Vertex Pharmaceuticals, Regeneron and GSK
by Zacks Equity Research
Novo Nordisk, Eli Lilly, Vertex Pharmaceuticals, Regeneron and GSK are included in this Analyst Blog.
5 Big Drug Stocks That May Continue to Outperform in 2024
by Kinjel Shah
Novo Nordisk (NVO), Eli Lilly (LLY), Vertex Pharmaceuticals (VRTX), Regeneron (REGN) and GSK (GSK) have been performing well this year. These stocks are poised to keep the momentum alive in 2024.
Gilead (GILD) Outperforms Industry in 6 Months: What Lies Ahead?
by Zacks Equity Research
Gilead (GILD) gains 3.7% in six months as its oncology portfolio gains traction and its HIV business maintains momentum.